BriaCell Therapeutics Corp. Common Shares (NASDAQ: BCTX)
$0.7700
+0.1680 ( +24.50% ) 3.0M
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Market Data
Open
$0.7700
Previous close
$0.6023
Volume
3.0M
Market cap
$21.79M
Day range
$0.6050 - $0.7910
52 week range
$0.4641 - $5.9700
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 28 | Nov 01, 2024 |
| 10-k | Annual reports | 104 | Oct 29, 2024 |
| 8-k | 8K-related | 26 | Oct 02, 2024 |
| 8-k | 8K-related | 18 | Oct 01, 2024 |
| 8-k | 8K-related | 24 | Sep 12, 2024 |
| 8-k | 8K-related | 20 | Sep 11, 2024 |
| 8-k | 8K-related | 14 | Aug 23, 2024 |
| 8-k | 8K-related | 18 | Jul 18, 2024 |
| 8-k | 8K-related | 14 | Jul 05, 2024 |
| 10-q | Quarterly Reports | 62 | Jun 14, 2024 |